Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 19, 2005

View Archived Issues

Altastaph reported to shorten hospital stay in adult patients with S. aureus bacteremia

Eszopiclone shows efficacy in insomnia associated with MDD

A specific inhibitor of Akt shows antitumor activity and low toxicity in rodents

Antiinflammatory activity of glabridin in a mouse sepsis model

TRPV1 agonist effective against urinary incontinence in preclinical model

Parenteral glutamine reported to increase hsp70 levels in critically ill patients

Melanocortin-4 receptor antagonist potentially useful for the treatment of cachexia

Similar efficacy found for darbepoetin alfa and epoetin alfa in chemotherapy-induced anemia

Data supports development of iroxanadine for cardiovascular diseases

Arimoclomol shows potential for type 2 diabetes in rat studies

Approvable letter for contrast agent MS-325

CR-001 shows potential as antithrombosis drug

Labopharm's once-daily tramadol approved in France

Alvesco launched in U.K.

Enrollment complete in phase I study of Davanat/5-FU

Two new phase II trials evaluate Discovery's Surfactant Replacement Therapy

Evidence suggests an association between resistin and insulin resistance in humans

New data on the pharmacokinetics and pharmacodynamics of oral insulin spray

Tea flavanoid tested in septic shock model

Novel, broad-spectrum chemokine inhibitor shows good pharmacological profile

AstraZeneca patent discloses delta-opioid agonists for pain

Scientists at CSIC report calpain inhibitors

Novel antimitotic compounds in early development at Cytokinetics

Antiinfective agents claimed by Dr. Reddy's

New compositions for cancer diagnosis and therapy

University of Pennsylvania scientists patent new methods for the treatment of cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...